TRDA
Entrada Therapeutics, Inc.
$6.56
Distressed or Transitioning
75%
Current EPS × Depressed Multiple
Strong
·
Conviction
Undervalued
Trading 51.3% below fair value
You pay
$6.56
Bear
$8.99
Fair
$13.48
Bull
$17.97
Bear
$8.99
+37.0%
EPS continues to decline, 5x multiple
Fair
$13.48
+105.5%
Current EPS stabilizes, 8x multiple
Bull
$17.97
+174.0%
Credible recovery, multiple re-rates to 10x
Key Value Driver
Whether the core business model is intact or structurally impaired
Implied Market Multiple
3.9x
Summary
Our base-case estimate uses Current EPS × Depressed Multiple. We then blend that result with the average analyst price target of $17.00 from 5 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $13.48 per share.
Warnings
Don't assume past cash flow levels will return — the company's troubles may have permanently reduced its ability to generate profits.
A stock can look cheap on paper and still lose half its value if the underlying business is permanently damaged.
The wide range between our best and worst cases is intentional — pretending to know a precise value for a troubled company would be misleading.
Wall Street's average price target is $17.00 (from 5 analysts). Our estimate is 26% below the consensus -- consider that gap carefully.
Key Risks
- Bullish DCF projections are fundamentally unknowable for distressed companies
- M&A speculation can floor the stock above intrinsic value temporarily
- Management credibility is a key input — new CEO expands the bull case